New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
12:25 EDTDD, STP, FSLR, TSL, CSIQ, JASO, ESLR, YGE, LDK, TEVA, CRL, PC, GILD, YMI, SPWROn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday as investors wait on the Fed and other Washington powers to set the direction. The averages began the session slightly higher and have remained in a narrow range all morning. However, the day's real action may be yet to come, as investors await the conclusion of the two-day Federal Reserve policy meeting. The rate decision is due out at 12:30 pm ET. And, as always, headlines from Washington regarding the fiscal cliff negotiations are always a threat to swing the market quickly in either direction... ECONOMIC EVENTS: In the U.S., import prices fell more than expected and recorded their biggest drop in five months in November, dropping 0.9%. In Europe, the pace of contraction of industrial production in the 17 countries that use the euro accelerated in October, as activity fell 3.6% from a year ago compared to a contraction of 2.8% in September... COMPANY NEWS: DuPont (DD) shares rose 2% after the company said it expects its adjusted EPS to come in at the high end of its previous forecast and also authorized a repurchase program of $1B... A number of solar stocks moved up sharply amid numerous headlines from Chinese and Taiwanese media sources. Reports said China plans additional subsidies for solar companies there and also some China-based makers may sell solar cell equipment to Taiwan. A number of solar names moved higher, including Yingli Green Energy (YGE), up 20%, Trina Solar (TSL), also up 20%, and JA Solar (JASO), up 22%. Additionally, LDK Solar (LDK), which rose 27%, announced it has entered into discussions with certain creditors to obtain additional flexibility as it continues to work to address its previously disclosed liquidity and working capital concerns... MAJOR MOVERS: Among the notable gainers was Panasonic (PC), up almost 8% following an upgrade to Overweight at Barclays. Also higher were shares of YM BioSciences (YMI), up 77% after agreeing to be acquired by Gilead Sciences (GILD) for $2.95 per share in cash. Gilead shares, meanwhile, moved up 10c, or 0.13%. Among the noteworthy losers was Charles River Labs (CRL) down 8% after reaffirming its 2012 guidance and giving guidance for 2013 below Street expectations. Also lower were shares of Teva Pharmaceutical (TEVA), down 4.7% after Leerink downgraded the stock to Market Perform and Wells Fargo removed it from the firm's Priority Stock List... INDICES: Near noon, the Dow was up 8.25, or 0.06%, to 13,256.69; the Nasdaq was down 2.71, or 0.09%, to 3,019.59; and the S&P 500 was up 2.37, or 0.17%, to 1,430.21.
News For DD;YMI;GILD;PC;CRL;TEVA;LDK;YGE;ESLR;JASO;CSIQ;TSL;FSLR;STP;SPWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 13, 2014
09:56 EDTGILDBernstein biotech analyst to hold an analyst/industry conference call
Subscribe for More Information
08:36 EDTGILDGilead HARVONI launch should be strong, says BMO Capital
Subscribe for More Information
08:17 EDTSPWRSunPower upgraded at Raymond James
As previously reported, Raymond James upgraded SunPower to Outperform. The firm upgraded shares citing reasonable valuation and believes there is a chance the company makes a yieldco announcement next month. Price target is $35.
07:56 EDTGILDGilead Harvoni pricing 'very reasonable,' says RBC Capital
Subscribe for More Information
07:39 EDTGILDPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
07:30 EDTSPWRSunPower upgraded to Outperform from Market Perform at Raymond James
Subscribe for More Information
05:34 EDTCSIQCanadian Solar reports sale of 24.3 MWp of modules to EDF Renewable Energy
Subscribe for More Information
05:24 EDTSPWRSunPower supplying 41 MW of high efficiency solar panels to La Compagnie du Vent
Subscribe for More Information
October 10, 2014
16:18 EDTSPWRCompuware announces spin-off of Covisint
Subscribe for More Information
14:08 EDTGILDGilead 12-week regimen of Harvoni to cost $94.5K
Gilead said its newly-approved treatment of hepatitis C genotype 1 infection, Harvoni, will be priced at $94,500 for a full 12 week regiment, according to multiple media outlets, which cite a company spokesperson.
13:55 EDTGILDGilead confirms FDA approval of Harvoni
Subscribe for More Information
13:42 EDTGILDGilead hepatitis C treatment Harvoni approved by FDA
The FDA announced the approval of Harvoni to treat chronic hepatitis C virus genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection, the agency stated. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection, it added. Harvoni is marketed by Gilead.
13:40 EDTGILDFDA approves Gilead hepatitus C treatment Harvoni
Subscribe for More Information
12:05 EDTDDUSDA raises U.S. corn production estimate to 14.475B
Subscribe for More Information
10:01 EDTDDOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:25 EDTLDKLDK Solar announces module supply pact with SNPTC
Subscribe for More Information
08:19 EDTGILDMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
08:06 EDTTSLTrina Solar announces sale of 10.6MW PV power plant in UK
Subscribe for More Information
07:21 EDTGILDFDA PDUFA Date for Gilead Sciences Sofosbuvir is October 10, 2014
Subscribe for More Information
05:43 EDTDDDuPont upgraded to Buy from Hold at Jefferies
Jefferies upgraded DuPont to Buy citing the pullback in shares and its belief the company's capital return program should sustain low-teens earnings growth. The firm raised its price target for shares to $84 from $72.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use